← Back to all trials
Completed
NCT05476484
Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma
Conditions: Allergic Rhinitis, Asthma, Allergy
Sex: All
Ages: 5 Years – N/A
Healthy volunteers: No
Enrollment: 46196
Sponsor: ALK-Abelló A/S
Location: ALK Hørsholm Copenhagen
Summary
To assess the impact of SQ SLIT-tablets (SQ Grass SLIT-tablet and SQ HDM SLIT-tablet) in Danish and Swedish allergic rhinitis (AR) patients, with or without asthma, between 2007-2020.
Eligibility Criteria
Inclusion Criteria:
AR-patients identified by having at least two dispensations of prescribed AR medications for two consecutive years and/or ICD10-codes of AR in specialty care
For the SQ SLIT-tablet cohort:
\- at least 2 dispensations within 365 days of SQ SLIT-tablets (ATC: V01AA02 and V01AA03)
For the control cohort:
\- unexposed subjects will be identified from the study population of AR-patients that may be eligible to receive SQ SLIT-tablets, but have not dispensed a prescription of SQ SLIT-tablets during the index year of the case or prior to that year
Exclusion Criteria:
\- Any allergy immunotherapy treatment prior to the index event
Source: ClinicalTrials.gov (NCT05476484). StuddyBuddy aggregates publicly available trial information.
